MedImmune Message Board - Msg: 19511989

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MedImmune

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (256)	11/17/2003 8:42:36 PM
From: Arthur Radley	Read Replies (1) of 416

MEDI will be taking it on the chin tomorrow...seems that Flumist might be a bust...miss revenue projections by a mile.. MedImmune cuts Q4, FY forecast on lower FluMist sales (MEDI) By Carolyn Pritchard SAN FRANCISCO (CBS.MW) -- MedImmune (MEDI) said late Monday that it was cutting its forecast for the fourth quarter and full year 2003, citing lower-than-expected demand for its nasal spray flu vaccine, FluMist. The Gaithersburg, Md.-based company said it now sees sales from the product coming in $55 million to $85 million instead of its previous forecast of $120 million to $140 million. As a result, MedImmune expects to post fourth-quarter earnings of 28 to 36 cents a share on sales of $385 million to $445 million, vs. previous expectations of a 44 to 49-cent per-share profit on sales of $450 million to $500 million. For the full year, the company sees earnings of 72 cents to 80 cents a share on sales of $1.04 billion to $1.1 billion, vs. prior guidance of 88 to 93 cents a share on sales of $1.1 billion to $1.15 billion. Shares of MedImmune ended Monday's session unchanged at $25.58.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next